RxDoctor Payments Data

Brian Billmeyer, MD

Urology · Merrillville, INNPI 1376688820

Payments from drug & device makers

$2,717in general payments, 2019–2025

Across 122 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$399
  • Neotract Inc.$333
  • Sumitomo Pharma America, Inc.$249
  • Olympus America Inc.$180
  • AbbVie$163
  • Johnson & Johnson$144
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,717 in reported general payments places this provider in the 40th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$302,431
Medicare patients
1,390
Services billed
6,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron147$139,245
GemtesaVibegron72$49,943
Solifenacin Succinate403$39,677
OrgovyxRelugolix14$34,071
Tamsulosin Hcl1,891$25,445
Mirabegron ErMirabegron24$16,190
Finasteride1,259$15,788
Oxybutynin Chloride ErOxybutynin Chloride165$4,843
Estradiol82$4,486
Silodosin32$3,463
Potassium Citrate ErPotassium Citrate24$3,251
Alfuzosin Hcl ErAlfuzosin Hcl186$3,202
Fesoterodine Fumarate ErFesoterodine Fumarate52$3,095
Trimethoprim86$2,985
Tadalafil43$2,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$399$139,245147 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$249$84,01486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 272 urology providers in Indiana.

Other urology in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →